All Other Chemical Product and Preparation Manufacturing (U.S., NAICS 32599)

A Histometrics rollup primer for public-market and private investors. NAICS (North American Industry Classification System) 2022 code 32599 — the five-digit industry that gathers three very different six-digit businesses under one roof.

---

1. Overview

NAICS 32599 is a holding pen for three unrelated specialty-chemical trades that the Census Bureau parks together because none fits a larger named category. It sits inside industry group 3259, "Other Chemical Product and Preparation Manufacturing," alongside paints, adhesives, soaps, printing ink and explosives. The three tenants are:

• 325991 — Custom Compounding of Purchased Resins: buy finished plastic pellets, melt-mix in additives and colorants, sell an upgraded "compound." A converting business that feeds nearly every molded plastic part.[1]
• 325992 — Photographic Film, Paper, Plate, Chemical & Copy Toner: coated imaging media and the chemistry that develops it — film, printing plates, laser-printer toner, X-ray film. A Bureau of Labor Statistics classification review observed that by 2017, copy toner had become "the only significant primary output remaining" in the category — a marker of how far the product mix has shifted from the industry's photographic origins.[1][2]
• 325998 — All Other Miscellaneous Chemical Product & Preparation: the true catch-all — activated carbon, antifreeze, pool sanitizers, gelatin, matches, fireworks, water- and metal-treating compounds.[1]

Why an investor should care about the rollup rather than the pieces: on the surface this looks like one $47-billion chemical industry with almost no concentration — the top four firms hold just 10% of revenue.[3] But that tidy average hides three businesses moving in different directions, owned by different kinds of people, on different economics. One is quietly growing (compounding), one is shrinking with a growing niche inside it (imaging), and one is a stable, fragmented sprawl with pockets of structural growth (misc chemicals). The distinctive value of reading them together is the contrast — which is where Section 2 starts.

Ways in (all indirect). None of the three has a clean public pure-play, and there is no ETF for 32599 or any of its children. Public exposure comes through diversified specialty-chemical companies where one of these trades is a segment. Private markets are where most of the industry actually lives — thousands of small blenders, compounders and formulators, heavy with family-succession situations and private-equity roll-ups. Tickers and named owners are held to Sections 4 and 10.

---

2. What's inside — the three children, and how they differ

This is the heart of the rollup. The three industries share a Census bin and almost nothing else.

Three takeaways from the contrast:

1. 325998 is the mass of the rollup (~60% of both sales and jobs) and drags the level's concentration down to almost nothing — its HHI of 121 is what makes the whole industry look unconcentrated.[3]
2. 325992 is the odd one out on structure. It is small (~10%) but the only concentrated child — a handful of capital-intensive coating plants supply the world, so top-4 share is 64% versus 16–22% in the other two.[3] The level's low HHI masks this pocket of oligopoly.
3. Direction of travel splits cleanly: compounding grows, imaging shrinks (with a reviving film corner), misc-chem holds steady. An investor should never treat 32599 as a single trend.

The common thread, if there is one: all three are residual/merchant codes — they capture the independent firms whose primary job is that activity, not the captive volume done inside bigger, differently-coded companies. That shared "leftovers" character drives the undercount caveat in Section 3.

---

3. How big it is (the rollup)

Federal figures for NAICS 32599 as a whole (our ground-truth ingested data):

Concentration for the level is strikingly low: CR4 10.0%, CR8 17.5%, CR20 32.3%, CR50 52.8%, HHI 72.8 — well under the 1,500 mark antitrust agencies treat as "moderately concentrated," and lower than any of the three children individually.[3] That is an artifact of addition: bolting three separate markets together dilutes any one firm's share. It does not mean the underlying businesses are uniformly competitive — 325992 is genuinely concentrated (Section 2). Treat the level HHI as an accounting sum, not a market reality.

Derived from the figures above: about $667,000 of receipts per worker and average pay near $79,000 — the signature of automated, material- and capital-intensive chemical plants rather than labor-heavy assembly.[3][4]

The rollup is clean. The three children's establishments (414 + 132 + 1,319 = 1,865), employees (21,623 + 6,258 + 42,583 = 70,464) and payroll all sum exactly to the level totals, and their receipts sum to ~$47.0B.[3][4] (Firm counts differ slightly — the children sum to ~1,545 versus 1,534 at the level — because a handful of companies operate in more than one of the three and are counted once here.)

Undercount caveat — read before comparing to any market-research number. Because all three children are residual, merchant codes, the $47.0B understates the real economic footprint of these products, and it does so most where small and captive activity dominates:

• Captive volume is invisible. A great deal of compounding is done in-house by resin makers and large molders (booked under resin/plastics codes, not 325991); much blending happens inside multi-product plants coded to something else.[1]
• Imports fill demand the manufacturing data can't see. A large share of toner cartridges, film, plates, consumer fireworks and some activated carbon sold in the U.S. is imported, so domestic-manufacturing receipts miss it.[11]
• The biggest players book elsewhere. Diversified chemical and imaging companies record most revenue under their primary code or overseas.

Read $47.0B as "the independent, merchant firms whose main business is one of these three trades," not as total U.S. output of these products. For scale, independent researchers size the whole U.S. specialty-chemicals universe (dozens of NAICS codes) at roughly $198–204 billion; 32599 is a narrow, mixed slice of it.[12] Treat any market-research total as a forward-looking estimate, not a reported government fact — and note that where individual and family ownership dominates (325991 and 325998), the count of the smallest operators is the softest part of the data.

---

4. The investable universe — where value concentrates across the children

There is no way to own 32599 as a unit. Value sits in three separate rosters, and the kind of investor each suits is different.

325991 (compounding) — public exposure is a segment inside larger chemical firms. The closest thing to a pure-play is Avient (NYSE: AVNT), a specialty formulator (~$3.2B sales, ~$3.4B market cap) that sold its distribution arm to focus on compounds and masterbatch.[13][14] Broader, diluted exposure comes via Celanese (NYSE: CE) (Engineered Materials), LyondellBasell (NYSE: LYB) (Advanced Polymer Solutions, the former A. Schulman) and the small, distressed Trinseo (NYSE: TSE); the international pure-play is HEXPOL (Nasdaq Stockholm), which began separating Thermoplastic Compounding as a distinct reporting segment in Q1 2026.[15][16] The real industry is private: Ravago, RTP Company, Teknor Apex, Techmer PM, Washington Penn (Audia Group), and Americhem (Pritzker Private Capital agreed in 2025 to acquire a majority stake) — family-owned compounders that never trade.[15][17]

325992 (imaging) — thin, idiosyncratic public exposure plus a PE core. The only U.S.-listed name with direct film/plate/chemistry manufacturing is Eastman Kodak (NYSE: KODK) (~$1.07B revenue in 2025, split between Print ~$715M and Advanced Materials & Chemicals ~$316M), but it is a small-cap turnaround where imaging shares the P&L with a pivot into advanced materials and pharma.[8] Toner exposure sits inside Xerox (NASDAQ: XRX) — which acquired Lexmark in 2025, combining two toner/printer franchises — and HP (NYSE: HPQ); Fujifilm (OTC: FUJIY) buries imaging inside a healthcare-and-materials conglomerate.[18] The concentrated core is largely private: Kodak Alaris (acquired by Kingswood Capital in August 2024), Carestream Health (Onex; its non-U.S. operations were separated and acquired by Midea at the end of 2025), and Harman/Ilford (UK, ~80% of black-and-white film).[19][20][21]

325998 (misc chemicals) — the widest public menu, all as segments. Closest fits: Ingevity (NYSE: NGVT) (activated carbon for auto emissions and PFAS water — Performance Materials segment generated $606.9M of 2025 sales at a 53.8% EBITDA margin), NewMarket (NYSE: NEU) and Innospec (NASDAQ: IOSP) (fuel/lubricant additives), Quaker Houghton (NYSE: KWR) (industrial process fluids), Hawkins (NASDAQ: HWKN) (water-treatment formulation and distribution).[9][22][23][24][25] Slices inside bigger names: Cabot (NYSE: CBT), Ecolab (NYSE: ECL) (water treatment), Darling Ingredients (NYSE: DAR) (gelatin via the ~$1.5B Rousselot–PB Leiner "Nextida" venture), Compass Minerals (NYSE: CMP) (salt), Occidental/OxyChem (NYSE: OXY) (pool chemicals).[9][26] The bulk of activity is private blenders and PE platforms — BioLab and Innovative Water Care (pool), Old World Industries and Recochem (antifreeze; Recochem bought the Prestone/Holts auto-care brands in 2024), Calgon Carbon (Kuraray), Wind Point Partners' Hasa (water and pool treatment), and Cargill/Morton (salt).[27][28][29]

Where value concentrates: by dollars, 325998 is the biggest field but the most diffuse (no single stock captures it); 325991 offers the cleanest single proxy (Avient); 325992 is where scarcity and concentration create the sharpest pricing power but the equity is small and fragile.

---

5. How the money works

Despite different products, the three children share one core economic engine: a conversion/formulation spread — the gap between input cost and a formulated selling price — multiplied by volume through a fixed-cost plant, with margin set by how specified-in (hard to substitute, qualified into a customer's process) the product is. Capacity utilization is the shared profit lever: an extra unit through an already-built line drops mostly to margin.

The variations that matter for the contrast:

• Input pass-through, on a lag. In compounding, resin is 60–80%+ of cost and passes through with a delay, so margins expand when resin prices fall and compress when they spike.[1] In misc-chem the same holds for ethylene glycol, chlorine, char and tallow; Quaker Houghton uses roughly 3,000 raw materials, many several generations downstream of crude oil and natural gas.[24] In imaging the swing input is silver (film/paper/X-ray are silver-halide) plus petrochemicals — a precious-metal price that flows straight into cost of goods.[7]
• Specialty vs. commodity mix. All three reward selling a specification over a tonne: engineered/medical/recycled compounds, registered pool sanitizers and automotive-qualified carbon, process-free printing plates. The better misc-chem operators run high-teens-to-~20% EBITDA margins (Cabot ~19% adjusted EBITDA); specialty segments can run far higher (Ingevity's Performance Materials at 53.8% segment EBITDA margin); commodity blending and toll work run thin single digits.[9][26] Toll-compounding fees for engineering plastics run roughly $0.50–$0.90 per kilogram.[30]
• The razor-and-blades / consumable core. Imaging is the purest version — the money is in film, cartridges, plates and chemistry bought over and over, not the hardware. Kodak posted a 22% gross margin and $62 million of operational EBITDA in 2025 as film volumes improved into paid-for fixed costs.[8] Compounding and many misc-chem lines (pool tablets, coolant, carbon) share the recurring-consumable character.
• Registration and qualification as moats. An EPA pesticide registration for a pool sanitizer, an automaker's emissions qualification for a carbon grade, FDA-grade gelatin, an OEM spec-in for an engineered compound — each takes years and locks in incumbents. This is the quiet barrier to entry across all three.
• Toll/custom (asset-light) models recur everywhere: blend or compound to a customer's recipe for a fee, holding little product risk — lower margin, lower capital, steadier cash.

The gauges to watch are the same trio in every child: utilization, value-add spread per unit, and product mix — the classic levers of a mid-cyclical converting manufacturer. This is not a rate-base, FFO or same-store-sales business.

---

6. What drives demand

Demand splits by child, which is exactly why the rollup's aggregate looks flat:

• Structural growth (325991): automotive lightweighting and electrification (an EV uses 2.5–4.0 km of wiring versus 1.0–1.8 km for a combustion car, plus needs flame-retardant, thermally stable compounds), the shift to halogen-free flame-retardant wire-and-cable, and recycled-content mandates — California's SB 54, for example, requires by 2032 a 25% reduction in plastic covered material versus baseline, recyclable or compostable covered material, and a 65% recycling rate.[5][6][31]
• Regulation-created growth (325998): EPA's 2024 PFAS drinking-water limits name granular activated carbon as a best-available treatment — a multi-year demand wave with compliance potentially extending to 2031 — and vehicle evaporative-emissions rules mandate carbon canisters on every gasoline vehicle.[10][32]
• Bifurcated demand (325992): analog film is reviving (the global photographic-film market is estimated around $2.9 billion in 2024, growing ~5% a year; Ilford's black-and-white film sales grew ~35% between 2020 and 2025) while office toner, offset newspaper plates and medical X-ray film are in slow, mostly structural decline — the number of film processors in North American hospitals fell to under 2,400 from about 9,800 a decade ago.[7][8][33][34]
• Shared cyclical base: all three feed autos, construction, packaging and industrial production, so volumes rise and fall with the industrial cycle. Add weather (de-icing salt, pool season) and consumer discretionary swings (pools, retail photo) on top.[9]

Net: two of the three children have a genuine multi-year tailwind (EV/HFFR/recycled compounds; PFAS carbon), the third is managing decline around a growing niche — over a cycle the rollup grows modestly, not dramatically.

---

7. Regulation

None of these is a licensed, rate-regulated industry; the regulatory weight is chemical, environmental and safety compliance — a steady cost that doubles as a moat and, increasingly, a demand creator.

• TSCA (Toxic Substances Control Act, EPA) governs the substances all three make and use; new additives face pre-manufacture review, and the PFAS reporting rule reaches persons that manufactured or imported covered PFAS during 2011–2022, pulling in fluoropolymer processing aids and some flame retardants.[9][35]
• FIFRA pesticide registration — pool and spa sanitizers are legally pesticides and must be EPA-registered, a barrier distinct from TSCA (325998).[35]
• FDA food-contact and food-additive rules — food-grade compounds and colorants, and gelatin/sugar-substitute ingredients (325991, 325998). FDA treats recycled food-contact resin case by case because contaminants may migrate into food.[36]
• Clean Water Act effluent and RCRA hazardous-waste rules bear hardest on imaging: federal limits on silver, cyanide and pH in photographic-processing wastewater, and mandatory silver recovery from spent fixer (325992).[7]
• DOT hazmat, OSHA process safety, and combustible-dust rules apply to oxidizers, flammables and extrusion dust across all three. OSHA's 2024 Hazard Communication revision defines combustible dust as finely divided particulates that pose a flash-fire or explosion hazard when dispersed — directly relevant to toner, pigment and polymer-powder handling.[37]
• State mandates and trade rules — California SB 54 recycled-content and Prop 65, EU REACH/RoHS for exporters, and tariffs on imported toner, film, carbon and fireworks.

Forward-looking judgment: the regulatory direction — tighter PFAS, emissions, recycled-content and chemical-safety rules — raises compliance costs but creates demand (flame-retardant/recycled compounds; PFAS carbon) and widens the moat around registered incumbents.

---

8. Consolidation

Every child is consolidating, but from different starting structures — which is the most investable contrast in the rollup:

• 325991 (fragmented → slow roll-up): hundreds of family compounders sit under a multinational top tier. Strategics buy bolt-ons — Celanese bought DuPont's Mobility & Materials and compounder Omni Plastics; HEXPOL runs a steady acquisition program (e.g., McCann Plastics); Avient reshaped itself into a formulator by selling its distribution arm.[15] PE is an active buyer (Pritzker Private Capital's 2025 Americhem deal; Nautic Partners' Aurora Material Solutions), cooled by higher rates in 2023–24.[17][38]
• 325992 (already consolidated, still combining): a brutal shakeout (Kodak's 2012 bankruptcy; Polaroid, Agfa restructurings) left a silver-halide quasi-oligopoly and a plate oligopoly. Consolidation continues at the top (Xerox acquired Lexmark in 2025) and PE keeps shuffling assets (Kodak Alaris to Kingswood, August 2024; Carestream's non-U.S. operations to Midea, end of 2025).[8][18][19][20]
• 325998 (barbell, buy-and-build): a few diversified giants over a very long tail of small blenders — ideal PE roll-up territory. Water treatment (Solenis to Platinum Equity), auto care (Recochem buying Prestone/Holts in 2024), pool treatment (Wind Point Partners' Hasa) and gelatin (Rousselot–PB Leiner "Nextida") have all been consolidated recently.[26][28][29]

A shared structural risk sharpens the M&A logic: single-plant fragility. Kodak's world film supply runs through Rochester; BioLab's 2020 and September 2024 pool-chemical fires illustrate the hazard — the Conyers, Georgia blaze forced roughly 17,000 residents to evacuate and approximately 90,000 shelter-in-place advisories, required removal of nearly 14 million pounds of reactive pool chemicals (against anticipated average inventory of approximately 6.2 million pounds), and led BioLab to decide not to rebuild manufacturing there.[7][39] For survivors, that concentration is a pricing tailwind.

---

9. Risks

Shared across the rollup:

• Input-cost and margin volatility — resin, silver, glycol, char and energy swing both margins (pass-through lag) and working capital.[1][7][9]
• Cyclicality and destocking — tied to autos, construction and industrial output; 2022–23 destocking hit volumes.[5]
• Regulatory/reformulation risk — PFAS, flame-retardant and additive restrictions can strand formulations and force costly requalification.[9][35]
• Single-plant / supply-concentration and safety tail risk — fires, outages and evacuations at coating and oxidizer plants carry liability and can halt supply nationwide. BLS reported a 2023 recordable injury and illness rate of 2.2 cases per 100 full-time workers for NAICS 325998.[7][39][40]
• Substitution and captive integration — large customers can insource compounding or blending.

Child-specific:

• 325991: loss of a spec'd-in OEM program; commoditization in toll/commodity grades; variable-quality recycled feedstock.[1]
• 325992: secular decline of office print, newspaper plates and medical film; a film revival that could plateau and strand new capacity; Kodak's balance-sheet and pension fragility; customer concentration (Kodak Alaris alone accounts for ~33% of Kodak's Advanced Materials & Chemicals segment revenue).[7][8]
• 325998: EV transition eroding evap-canister carbon and conventional antifreeze; import competition; weather dependence; catastrophic hazmat tail risk.[10][39]

---

10. How to invest, and the outlook

Public routes are indirect in every child. You cannot buy 32599; you buy a diversified chemical or imaging company where one of these trades is a segment, and you accept the rest of the business with it:

• Compounding: Avient (AVNT) is the cleanest proxy; Celanese (CE), LyondellBasell (LYB) and Trinseo (TSE) are more diluted; HEXPOL (Stockholm) is the international pure-play with a newly separated thermoplastic-compounding segment.[13][15][16]
• Imaging: Eastman Kodak (KODK) is the only direct U.S. name and a whole-company turnaround bet; Xerox (XRX, now combined with Lexmark), Fujifilm (FUJIY) and HP (HPQ) offer diluted toner exposure.[8][18]
• Misc chemicals: Ingevity (NGVT), NewMarket (NEU), Innospec (IOSP), Quaker Houghton (KWR) and Hawkins (HWKN) are the closest fits; Cabot (CBT), Ecolab (ECL), Darling (DAR), Compass (CMP) and Occidental (OXY) hold slices.[9]

In every case, read the segment disclosures, watch input spreads, utilization and volume/destocking commentary, and treat dividend yields and valuation multiples as you would any mid-cyclical industrial-chemical name — never as a proxy for the whole 32599 bin, which is too diffuse to value as a unit.

Private routes are the more direct way in — and where most of the industry lives. All three children are heavy with founder- and family-owned businesses facing succession, plus active PE:

• 325991: direct acquisition or roll-ups of specialty/recycled-content compounders; diligence on customer/spec concentration, utilization headroom, formulation IP and EV/medical/HFFR exposure.
• 325992: PE buyouts and secondaries (Kingswood, Onex) and niche film/imaging-chemistry franchises — illiquid, concentrated bets on scarcity-priced consumable streams.
• 325998: buy-and-build platforms and search-fund targets in the fragmented blender tail; diligence on feedstock pass-through, EPA/FDA registrations, customer concentration and single-plant/environmental liability.

Outlook (forward-looking). The rollup's aggregate motion is modest, but the mix inside it improves: compounding rides EV, halogen-free wire-and-cable and legislated recycled content (~7% market CAGR); misc-chem gains a multi-year PFAS-carbon tailwind (with compliance potentially extending to 2031) and firm pool-sanitizer pricing after the BioLab closure; imaging keeps shrinking in the office/medical core while a scarcity-priced analog-film niche grows (Ilford's black-and-white film sales up ~35% over five years). Against those, the whole industry stays exposed to the industrial cycle, input-price swings and single-plant safety risk, so results will stay lumpy quarter to quarter. Net judgment: 32599 is not a sector to own as a unit — it is three separable bets. Approach it child-by-child: the growth-and-mix story is in compounding and PFAS-carbon; the scarcity-and-pricing story is in surviving imaging niches; the value in all three accrues to operators who keep their lines full, hold their registrations and specifications, and move mix toward the products regulation and end-markets are pulling on.

---

Sources

1. U.S. Census Bureau / NAICS Association, 2022 NAICS definitions — 3259 group; 325991, 325992, 325998. https://www.census.gov/naics/?year=2022
2. Bureau of Labor Statistics, NAICS Revision Submission — NAICS 325992 (2017 data: 193 firms, 208 establishments, $7.070B; observation that copy toner was "the only significant primary output remaining"). https://downloads.regulations.gov/USBC-2020-0004-0057/attachment_1.pdf
3. U.S. Census Bureau, 2022 Economic Census — Concentration ratios, receipts, firm counts and HHI, NAICS 32599 and children 325991 / 325992 / 325998 (Histometrics ingested federal data): level receipts $47.0B, firms 1,534, CR4 10.0%, CR8 17.5%, CR20 32.3%, CR50 52.8%, HHI 72.8; child receipts $13.69B / $4.90B / $28.4B; child HHIs 240.6 / ~1,252 / 121.2. https://www.census.gov/programs-surveys/economic-census.html
4. U.S. Census Bureau, County Business Patterns 2023, NAICS 32599 and children (Histometrics ingested federal data): level establishments 1,865, employees 70,464, annual payroll $5.57B, Q1 payroll $1.41B; child establishments 414 / 132 / 1,319; child employment 21,623 / 6,258 / 42,583. https://www.census.gov/programs-surveys/cbp.html
5. Grand View Research, U.S. Plastic Compounding Market Size, Report to 2030 (~7% CAGR), 2024. https://www.grandviewresearch.com/industry-analysis/us-plastic-compounding-market-report
6. IndexBox, Automotive Wiring / Wire-and-Cable Compound Forecasts to 2035 (EV wiring 2.5–4.0 km vs. 1.0–1.8 km for combustion; HFFR shift), 2025. https://www.indexbox.io/blog/automotive-wiring-compounds-market-forecast-points-higher-toward-2035-as-vehicle-electrification-accelerates-demand/
7. Craig Bettenhausen, "Film photography is coming back. Can manufacturers keep up?," Chemical & Engineering News (ACS), 2026. https://cen.acs.org/business/specialty-chemicals/Film-photography-coming-back-manufacturers/104/web/2026/04
8. Eastman Kodak Company, Form 10-K for fiscal year 2025 (revenue $1.069B; Print $715M; AM&C $316M; 22% gross margin, $62M operational EBITDA; AM&C margin improvement; Kodak Alaris ~33% of AM&C revenue), 2026. https://www.sec.gov/Archives/edgar/data/31235/000119312526104214/kodk-20251231.htm
9. Ingevity Corporation, Form 10-K for fiscal year 2025 (Performance Materials $606.9M sales, 53.8% EBITDA margin; 10 largest automotive-carbon customers ~90% of segment sales; principal inputs sawdust and phosphoric acid), 2026. https://www.sec.gov/Archives/edgar/data/1653477/000165347726000014/ngvt-20251231.htm
10. U.S. EPA, Final PFAS National Primary Drinking Water Regulation (granular activated carbon named Best Available Technology; phased compliance from June 2024), 2024. https://www.epa.gov/system/files/documents/2024-04/pfas-npdwr_fact-sheet_treatment_4.8.24.pdf
11. IntelMarketResearch / GMInsights, Digital Offset Printing Plate Market Outlook (China share; import supply), 2025–2026. https://www.intelmarketresearch.com/global-digital-offset-printing-plate-forecast-market-18871
12. Market Data Forecast / Polaris Market Research, U.S. Specialty Chemicals Market Size (2024–2025, ~$198–204B), 2025. https://www.marketdataforecast.com/market-reports/us-specialty-chemicals-market
13. Avient Corporation, Form 10-K, FY2025, U.S. Securities and Exchange Commission, 2026. https://www.sec.gov/Archives/edgar/data/1122976/000112297626000039/avnt-20251231.htm
14. StockAnalysis.com, "Avient (AVNT) Market Cap & Net Worth" (~$3.4B), 2026. https://stockanalysis.com/stocks/avnt/market-cap/
15. Plastics News, "Mergers and acquisitions in plastics compounding slower, but still active"; PlasticsToday, "Celanese to acquire Omni Plastics"; HEXPOL McCann Plastics acquisition (2022–2024). https://www.plasticsnews.com/news/mergers-and-acquisitions-plastics-compounding-slower-still-active
16. HEXPOL AB, 2025 Annual Report with Sustainability Report (Thermoplastic Compounding segment separated Q1 2026; 13 production units, 800 employees in 2025), 2026. https://www.hexpol.com/wp-content/uploads/2026/04/file-2025-HEXPOL-Annual-Report-with-Sustainability-Report.pdf
17. Americhem, "Pritzker Private Capital Agrees to Invest in Americhem" (majority stake, 2025). https://www.americhem.com/news/pritzker-private-capital-agrees-to-invest-in-americhem/
18. Reporting on Xerox acquisition of Lexmark (Lexington, KY toner/printer operations), 2025. https://www.encyclopedia.com/social-sciences-and-law/economics-business-and-labor/businesses-and-occupations/lexmark-international-inc
19. Kodak Alaris, Acquisition by Kingswood Capital Management, August 2024. https://corporate.kodakalaris.com/Pressroom/News/2024/Kodak-Alaris-Announces-Acquisition-by-Kingswood-Ca
20. Carestream Health, Carestream Health Completes Separation into Two Companies to Accelerate Growth (Midea acquisition of non-U.S. operations, end of 2025). https://www.carestream.com/en/us/newsandevents/news-releases/2026/carestream-health-completes-separation-into-two-companies-to-accelerate-growth
21. CamerAgX, "Who's really manufacturing film in 2025?" (Kodak, Harman/Ilford ~80% of B&W, Fujifilm), 2025. https://cameragx.com/2025/09/09/whos-really-manufacturing-film-in-2025/
22. NewMarket Corporation, Fourth Quarter and Full Year 2024 Results (petroleum-additives segment ~$2.6B), 2025. https://www.newmarket.com/news/2025/02/newmarket-corporation-reports-fourth-quarter-and-full-year-2024-results/
23. Innospec Inc., Fourth Quarter and Full Year 2024 Financial Results (total revenue ~$1.85B), 2025. https://www.sec.gov/Archives/edgar/data/1054905/000095017025022803/iosp-20241231.htm
24. Quaker Houghton, Form 10-K for fiscal year 2025 (~$1.84B; ~3,000 raw materials), 2026. https://www.sec.gov/Archives/edgar/data/81362/000162828026010694/kwr-20251231.htm
25. Hawkins, Inc., Form 10-K for fiscal year 2025 and fiscal 2026 fourth-quarter results (Water Treatment segment $543.3M sales, 26.7% gross margin, 12.5% operating margin), 2025–2026. https://www.sec.gov/Archives/edgar/data/46250/000004625025000025/hwkn-20250330.htm
26. Cabot Corporation, Fourth Quarter and Fiscal Year 2024 Results (revenue ~$4.0B; ~19% adj. EBITDA margin); Nutrition Insight, "Rousselot and PB Leiner to combine in Nextida" (~$1.5B revenue), 2024. https://investor.cabot-corp.com/news-releases/news-release-details/cabot-corp-reports-fourth-quarter-and-fiscal-year-2024-results
27. C&EN (ACS), "Shortages of trichlor, a popular pool sanitizer, threaten summer fun," 2021. https://cen.acs.org/business/specialty-chemicals/Shortages-trichlor-popular-pool-sanitizer/99/i17
28. Wind Point Partners, "Wind Point Partners Acquires Hasa," 2024. https://www.wppartners.com/wind-point-partners-acquires-hasa/
29. Persistence Market Research / F&L Asia, "North America antifreeze & coolant market; Recochem acquires KIK's Prestone/Holts auto-care business" (2024). https://www.persistencemarketresearch.com/market-research/north-america-antifreeze-and-coolants-market.asp
30. Polymer Compounders, "The Ultimate Guide to Toll Compounding: Process, Costs & Vendor Selection" (~$0.50–$0.90/kg toll fees), 2026. https://polymer-compounders.com/toll-compounding/
31. California Department of Resources Recycling and Recovery (CalRecycle), "SB 54 Plastic Pollution Prevention and Packaging Producer Responsibility Act — Requirements" (by 2032: 25% reduction, recyclable/compostable, 65% recycling rate). https://calrecycle.ca.gov/laws/rulemaking/sb54regulations/
32. U.S. EPA, "Per- and Polyfluoroalkyl Substances (PFAS) — Current Rule Status" (compliance potentially extending to 2031), 2025. https://www.epa.gov/sdwa/and-polyfluoroalkyl-substances-pfas
33. Cognitive Market Research, Photographic Film Market Report (~$2.86B 2024, ~5% CAGR); Ilford black-and-white film sales +35% 2020–2025, 2024. https://www.cognitivemarketresearch.com/photographic-film-market-report
34. MarketGrowthReports, X-ray Film Market (~$1.09B 2024, ~2.4% CAGR; film processors in North American hospitals under 2,400 from ~9,800 a decade ago), 2024. https://www.marketgrowthreports.com/market-reports/x-ray-film-market-113986
35. Federal Register / U.S. EPA, Updates to New Chemicals Regulations under TSCA (effective Jan 2025); FIFRA pesticide registration; PFAS reporting rule (2011–2022 window), 2024–2025. https://www.federalregister.gov/documents/2024/12/18/2024-28870/updates-to-new-chemicals-regulations-under-the-toxic-substances-control-act-tsca
36. U.S. Food and Drug Administration, "Guidance for Industry: Use of Recycled Plastics in Food Packaging — Chemistry Considerations." https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-use-recycled-plastics-food-packaging-chemistry-considerations
37. U.S. Occupational Safety and Health Administration, "Hazard Communication Final Rule — Economic Analysis" (2024 revision; combustible dust definition), 2024. https://public-inspection.federalregister.gov/2024-08568.pdf
38. Aurora Material Solutions, "About Aurora Material Solutions" (Nautic Partners-backed). https://www.auroramaterialsolutions.com/company/about-aurora-material-solutions/
39. U.S. Chemical Safety Board / U.S. OSHA, "CSB Releases BioLab Conyers Final Investigation Report" (Sept 2024; ~17,000 evacuated, ~90,000 shelter-in-place; nearly 14M lbs reactive chemicals removed vs. ~6.2M avg inventory; BioLab will not rebuild); OSHA proposed $61,473 penalties, 2024–2025. https://www.csb.gov/csb-releases-bio-lab-conyers-final-investigation-report/
40. U.S. Bureau of Labor Statistics, "Table 1. Incidence rates of nonfatal occupational injuries and illnesses by industry, 2023" (NAICS 325998: 2.2 cases per 100 FTE workers), 2024. https://www.bls.gov/iif/nonfatal-injuries-and-illnesses-tables/table-1-injury-and-illness-rates-by-industry-2023-national.htm